BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15276492)

  • 1. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
    Beseth BD; Cameron RB; Leland P; You L; Varricchio F; Kreitman RJ; Maki RA; Jablons DM; Husain SR; Puri RK
    Ann Thorac Surg; 2004 Aug; 78(2):436-43; discussion 436-43. PubMed ID: 15276492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo.
    Leland P; Taguchi J; Husain SR; Kreitman RJ; Pastan I; Puri RK
    Mol Med; 2000 Mar; 6(3):165-78. PubMed ID: 10965493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
    Puri RK; Hoon DS; Leland P; Snoy P; Rand RW; Pastan I; Kreitman RJ
    Cancer Res; 1996 Dec; 56(24):5631-7. PubMed ID: 8971168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma.
    Kreitman RJ; Puri RK; Pastan I
    Cancer Res; 1995 Aug; 55(15):3357-63. PubMed ID: 7614471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.
    Stish BJ; Oh S; Chen H; Dudek AZ; Kratzke RA; Vallera DA
    Br J Cancer; 2009 Oct; 101(7):1114-23. PubMed ID: 19755995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy.
    Husain SR; Behari N; Kreitman RJ; Pastan I; Puri RK
    Cancer Res; 1998 Aug; 58(16):3649-53. PubMed ID: 9721874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma.
    Ishige K; Shoda J; Kawamoto T; Matsuda S; Ueda T; Hyodo I; Ohkohchi N; Puri RK; Kawakami K
    Int J Cancer; 2008 Dec; 123(12):2915-22. PubMed ID: 18798553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
    Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
    Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cintredekin besudotox in treatment of malignant glioma.
    Mut M; Sherman JH; Shaffrey ME; Schiff D
    Expert Opin Biol Ther; 2008 Jun; 8(6):805-12. PubMed ID: 18476792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo studies of antitumor effects of the recombinant immunotoxin MSH-PE38KDEL on melanoma.
    Hui Q; Ma J; Song J; Liu Z; Ren H; Jiang W; Wang Y; Xu Y; Guo D; Zhang X; Lu S
    Neoplasma; 2014; 61(4):392-400. PubMed ID: 25027740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification, characterization, and targeting of IL-4 receptor by IL-4-Pseudomonas exotoxin in mouse models of anaplastic thyroid cancer.
    Joshi BH; Suzuki A; Fujisawa T; Leland P; Varrichio F; Lababidi S; Lloyd R; Kasperbauer J; Puri RK
    Discov Med; 2015 Nov; 20(111):273-84. PubMed ID: 26645899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy.
    Joshi BH; Leland P; Calvo A; Green JE; Puri RK
    Cancer Res; 2008 Nov; 68(22):9311-7. PubMed ID: 19010904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models.
    Strome SE; Kawakami K; Alejandro D; Voss S; Kasperbauer JL; Salomao D; Chen L; Maki RA; Puri RK
    Clin Cancer Res; 2002 Jan; 8(1):281-6. PubMed ID: 11801570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity.
    Puri RK; Leland P; Obiri NI; Husain SR; Mule J; Pastan I; Kreitman RJ
    Cell Immunol; 1996 Jul; 171(1):80-6. PubMed ID: 8660841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein.
    Joshi BH; Leland P; Silber J; Kreitman RJ; Pastan I; Berger M; Puri RK
    Br J Cancer; 2002 Jan; 86(2):285-91. PubMed ID: 11870521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.
    Kawakami M; Kawakami K; Stepensky VA; Maki RA; Robin H; Muller W; Husain SR; Puri RK
    Clin Cancer Res; 2002 Nov; 8(11):3503-11. PubMed ID: 12429641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model.
    Husain SR; Kreitman RJ; Pastan I; Puri RK
    Nat Med; 1999 Jul; 5(7):817-22. PubMed ID: 10395328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.
    Shimamura T; Fujisawa T; Husain SR; Joshi B; Puri RK
    Clin Cancer Res; 2010 Jan; 16(2):577-86. PubMed ID: 20068108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxins directed at interleukin-4 receptors as therapy for human brain tumors.
    Puri RK
    Methods Mol Biol; 2001; 166():155-76. PubMed ID: 11217365
    [No Abstract]   [Full Text] [Related]  

  • 20. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
    Chen H; Gao J; Lu Y; Kou G; Zhang H; Fan L; Sun Z; Guo Y; Zhong Y
    J Control Release; 2008 Jun; 128(3):209-16. PubMed ID: 18450313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.